a). administering to said individual a pharmacologically effective dose of a [agent] retinoid which up-regulates the expression of [a cellular target] CD38 antigen; and,

b). administering to the same individual a pharmacologically effective dose of an immunotoxin directed against the up-regulated [cellular target] CD38 antigen.

Please amend claim 5 as follows:

5. The method of claim [3] 1, wherein said retinoid is a material selected from the group consisting of all-*trans*-retinoic acid (RA); 9-*cis* retinoic acid (9-cis RA); (*E*)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-nephthalenyl)-1-propenyl]benzoic acid (TTNPB); and, (*E*)-4-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-nephthalenyl)-1-propenyl]benzoic acid (3-met TTNPB).

In claim 7, line 1, replace "claim 3" with --claim 1--.

Please cancel claims 2, 3, 4 and 10.